-
公开(公告)号:US20170258891A1
公开(公告)日:2017-09-14
申请号:US15498556
申请日:2017-04-27
申请人: Christopher L. Parks , Maoli Yuan , Xinsheng Zhang , Aaron Wilson , Angela Grazia Lombardo , Eddy Sayeed , Josephine Helena Cox , Takashi Hironaka , Makoto Inoue , Hiroto Hara
发明人: Christopher L. Parks , Maoli Yuan , Xinsheng Zhang , Aaron Wilson , Angela Grazia Lombardo , Eddy Sayeed , Josephine Helena Cox , Takashi Hironaka , Makoto Inoue , Hiroto Hara
CPC分类号: A61K39/21 , A61K39/12 , A61K2039/5256 , A61K2039/53 , A61K2039/543 , A61K2039/545 , A61K2039/55511 , A61K2039/55555 , A61K2039/57 , A61K2039/575 , A61K2039/70 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2740/16034 , C12N2740/16134 , C12N2740/16234 , C12N2740/16271 , C12N2740/16334 , C12N2760/18443 , C12N2760/18843 , C12N2760/18871 , C12N2760/20243
摘要: The present invention relates to a vector(s) containing and expressing an optimized HIV EnvF gene, methods for making the same and cell substrates qualified for vaccine production which may comprise vector(s) containing optimized HIV genes.
-
2.
公开(公告)号:US20170258890A1
公开(公告)日:2017-09-14
申请号:US15498554
申请日:2017-04-27
申请人: John Coleman , Josephine Helena Cox , Arban Domi , Hiroto Hara , Takashi Hironaka , Makoto Inoue , Dagna Skoog Laufer , Angela Grazia Lombardo , Christopher L. Parks , Eddy Sayeed , Maoli Yuan , Xinsheng Zhang
发明人: John Coleman , Josephine Helena Cox , Arban Domi , Hiroto Hara , Takashi Hironaka , Makoto Inoue , Dagna Skoog Laufer , Angela Grazia Lombardo , Christopher L. Parks , Eddy Sayeed , Maoli Yuan , Xinsheng Zhang
IPC分类号: A61K39/21 , C07K14/005 , C12N15/86 , C12N7/00
CPC分类号: A61K39/21 , A61K39/12 , A61K2039/5256 , A61K2039/53 , A61K2039/543 , A61K2039/545 , A61K2039/55511 , A61K2039/55555 , A61K2039/57 , A61K2039/575 , A61K2039/70 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2740/16034 , C12N2740/16134 , C12N2740/16234 , C12N2740/16271 , C12N2740/16334 , C12N2760/18443 , C12N2760/18843 , C12N2760/18871 , C12N2760/20243
摘要: The present invention relates to genetically stable replication competent Sendai virus vector(s) containing optimized HIV genes, methods for making the same and cell substrates qualified for vaccine production which may comprise genetically stable replication competent Sendai virus vector(s) containing optimized HIV genes.
-